Ensuring sample quality for blood biomarker studies in clinical trials: A multicenter international study for plasma and serum sample preparation

Translational Lung Cancer Research

Volumn 6, Issue 6, 2017, Pages 625-634

  Kong, Feng Ming Spring ^a   Zhao, Lujun ^b   Wang, Luhua ^c   Chen, Yuhchyau ^d   Hu, Jie ^e   Fu, Xiaolong ^f   Bai, Chunxue ^e   Wang, Li ^g   Lawrence, Theodore S ^h   Anscher, Mitchell S ^g   Dicker, Adam ⁱ   Okunieff, Paul ^j  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d UNIVERSITY OF ROCHESTER   (United States)

^e FUDAN UNIVERSITY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY   (China)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^j UNIVERSITY OF FLORIDA   (United States)

more..

Author keywords

Biomarker study; Plasma; Platelet factor 4 (PF4); Serum

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; EOTAXIN; EPIDERMAL GROWTH FACTOR; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; THROMBOCYTE FACTOR 4; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL EVALUATION; CLINICAL TRIAL; ENVIRONMENTAL TEMPERATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE QUALITY; HUMAN; HUMAN EXPERIMENT; MULTICENTER STUDY; NORMAL HUMAN; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; ROOM TEMPERATURE; SPECIMEN HANDLING; THROMBOCYTE ACTIVATION; THROMBOCYTE POOR PLASMA;

EID: 85031323584     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.21037/tlcr.2017.09.13     Document Type: Article

References (30)

1. Greco V, Piras C, Pieroni L, et al. Direct Assessment of Plasma/Serum Sample Quality for Proteomics Biomarker Investigation. Methods Mol Biol 2017;1619:3-21.
2. Kong FM, Anscher MS, Jirtle RL. Transforming Growth Factor Beta: A Plasma Tumor Marker In: Hanausek M, Walaszek Z. editors. Methods in Molecular Biology: Tumor Marker Protocols. New Jersey: Human Press Inc., 1997:417-30.
3. Anscher MS, Kong FM, Marks LB, et al. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 1997;37:253-8.
4. Anscher MS, Kong FM, Andrews K, et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998;41:1029-35.
5. Fu XL, Huang H, Bentel G, et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 2001;50:899-908.
6. Rabbani ZN, Anscher MS, Zhang X, et al. Soluble TGFbeta type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. Int J Radiat Oncol Biol Phys 2003;57:563-72.
7. Nishioka A, Ogawa Y, Mima T, et al. Histopathologic amelioration of fibroproliferative change in rat irradiated lung using soluble transforming growth factor-beta (TGF-beta) receptor mediated by adenoviral vector. Int J Radiat Oncol Biol Phys 2004;58:1235-41.
8. De Jaeger K, Seppenwoolde Y, Kampinga HH, et al. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;58:1378-87.
9. Anscher MS, Kong FM. In regard to De Jaeger et al.: significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer (Int J Radiat Oncol Biol Phys 2004;58:1378-1387). Int J Radiat Oncol Biol Phys 2005;61:1276-7.
10. De Jaeger K, Seppenwoolde Y, Lebesque JV, et al. In response to Drs. Anscher and Kong. Int J Radiat Oncol Biol Phys 2005;63:308.
11. Zhao L, Wang L, Ji W, et al. The influence of the blood handling process on the measurement of circulating TGF-beta1. Eur Cytokine Netw 2012;23:1-6.
12. Grainger DJ, Mosedale DE, Metcalfe JC. TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev 2000;11:133-45.
13. Assoian RK, Komoriya A, Meyers CA, et al. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 1983;258:7155-60.
14. Alessandro R, Fontana S, Kohn E, et al. Proteomic strategies and their application in cancer research. Tumori 2005;91:447-55.
15. Banks RE, Stanley AJ, Cairns DA, et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 2005;51:1637-49.
16. Tammen H, Schulte I, Hess R, et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 2005;5:3414-22.
17. Wakefield LM, Letterio JJ, Chen T, et al. Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1995;1:129-36.
18. Jeon JH, Kim YS, Choi EJ, et al. Implication of co-measured platelet factor 4 in the reliability of the results of the plasma transforming growth factor-beta 1 measurement. Cytokine 2001;16:102-5.
19. Ao X, Lubman DM, Davis MA, et al. Comparative proteomic analysis of radiation-induced changes in mouse lung: fibrosis-sensitive and-resistant strains. Radiat Res 2008;169:417-25.
20. Cai XW, Shedden K, Ao X, et al. Plasma proteomic analysis may identify new markers for radiation-induced lung toxicity in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2010;77:867-76.
21. Wang S, Campbell J, Stenmark MH, et al. Plasma Levels of IL-8 and TGF-beta1 Predict Radiation-Induced Lung Toxicity in Non-Small Cell Lung Cancer: A Validation Study. Int J Radiat Oncol Biol Phys 2017;98:615-21.
22. Kong FM, Wang S. Nondosimetric risk factors for radiation-induced lung toxicity. Semin Radiat Oncol 2015;25:100-9.
23. Zhao L, Wang L, Ji W, et al. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan. Int J Radiat Oncol Biol Phys 2009;74:1385-90.
24. Novakova-Jiresova A, Van Gameren MM, Coppes RP, et al. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 2004;71:183-9.
25. Findeisen P, Thumfart JO, Costina V, et al. MS-based monitoring of proteolytic decay of synthetic reporter peptides for quality control of plasma and serum specimens. Am J Clin Pathol 2013;140:314-23.
26. Qundos U, Hong MG, Tybring G, et al. Profiling post-centrifugation delay of serum and plasma with antibody bead arrays. J Proteomics 2013;95:46-54.
27. Mateos J, Carneiro I, Corrales F, et al. Multicentric study of the effect of pre-analytical variables in the quality of plasma samples stored in biobanks using different complementary proteomic methods. J Proteomics 2017;150:109-20.
28. Tuck MK, Chan DW, Chia D, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 2009;8:113-7.
29. Rai AJ, Vitzthum F. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics 2006;3:409-26.
30. Shabihkhani M, Lucey GM, Wei B, et al. The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. Clin Biochem 2014;47:258-66.